-
Learning imaging in axial spondyloarthritis: more than just a matter of experience RMD Open (IF 6.2) Pub Date : 2024-03-01 Felix Radny, Katharina Ziegeler, Iris Eshed, Juliane Greese, Dominik Deppe, Carsten Stelbrink, Robert Biesen, Hildrun Haibel, Valeria Rios Rodriguez, Judith Rademacher, Mikhail Protopopov, Fabian Proft, Kay Geert A Hermann, Denis Poddubnyy, Torsten Diekhoff, Sevtap Tugce Ulas
Objective Reliable interpretation of imaging findings is essential for the diagnosis of axial spondyloarthritis (axSpA) and requires a high level of experience. We investigated experience-dependent differences in diagnostic accuracies using X-ray (XR), MRI and CT. Methods This post hoc analysis included 163 subjects with low back pain. Eighty-nine patients had axSpA, and 74 patients had other conditions
-
Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose? RMD Open (IF 6.2) Pub Date : 2024-03-01 Catia Duarte, Ricardo J O Ferreira, Paco M J Welsing, Johannes W G Jacobs, Laure Gossec, Pedro M Machado, Désirée van der Heijde, Jose Antonio Pereira da Silva
Objective To assess which definition of remission best predicts good radiographic outcome (GRO) and good functional outcome (GFO) in rheumatoid arthritis, focusing the updated American College of Rheumatology/European Alliance of Associations for Rheumatology criteria. Material and methods Meta-analyses of individual patient data (IPD) from randomised controlled trials (RCTs). Six definitions of remission
-
Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study RMD Open (IF 6.2) Pub Date : 2024-03-01 Faustino Peron Filho, Andressa de Souza Moreira, Anna Larissa Faria Janes, Alexandre W S de Souza
Objective This study aims to evaluate the effectiveness and safety of adalimumab (ADA) compared with leflunomide (LEF) in patients with Takayasu arteritis (TAK). Method A retrospective cohort study was performed with the following inclusion criteria: the fulfilment of the 2022 American College Classification/European Alliance of Associations for Rheumatology criteria for TAK, age ≥18 years, and written
-
Validity of an ultrasonographic joint-specific scoring system in juvenile idiopathic arthritis: a cross-sectional study comparing ultrasound findings of synovitis with whole-body magnetic resonance imaging and clinical assessment RMD Open (IF 6.2) Pub Date : 2024-03-01 Nina Krafft Sande, Eva Kirkhus, Vibke Lilleby, Anders Høye Tomterstad, Anna-Birgitte Aga, Berit Flatø, Pernille Bøyesen
Objective To assess the validity of an ultrasonographic scoring system in juvenile idiopathic arthritis (JIA) by comparing ultrasound detected synovitis with whole-body MRI and clinical assessment of disease activity. Methods In a cross-sectional study, 27 patients with active JIA underwent clinical 71-joints examination, non-contrast enhanced whole-body MRI and ultrasound evaluation of 28 joints (elbow
-
Re-evaluating the mythical divide between traditional and novel cardiovascular risk factors in rheumatoid arthritis RMD Open (IF 6.2) Pub Date : 2024-03-01 Eirik Ikdahl, Mats Julius Stensrud
Cardiovascular (CV) risk factors for rheumatoid arthritis (RA) are conventionally classified as ‘traditional‘ and ‘novel‘. We argue that this classification is obsolete and potentially counterproductive. Further, we discuss problems with the common practice of adjusting for traditional CV risk factors in statistical analyses. These analyses do not target well-defined effects of RA on CV risk. Ultimately
-
Concordance and agreement between different activity scores in polymyalgia rheumatica RMD Open (IF 6.2) Pub Date : 2024-03-01 Justine D'Agostino, Aghiles Souki, Anne Lohse, Guillermo Carvajal Alegria, Emanuelle Dernis, Christophe Richez, Marie-Elise Truchetet, Daniel Wendling, Eric Toussirot, Aleth Perdriger, Jacques-Eric Gottenberg, Renaud Felten, Bruno Fautrel, Laurent Chiche, Pascal Hilliquin, Catherine Le Henaff, Benjamin Dervieux, Guillaume Direz, Isabelle Chary-Valckenaere, Divi Cornec, Dewi Guellec, Thierry Marhadour
Objective The C reactive protein polymyalgia rheumatica activity score (CRP-PMR-AS) is a composite index that includes CRP levels and was developed specifically for PMR. As treatments such as interleukin-6 antagonists can normalise CRP levels, the erythrocyte sedimentation rate (ESR) of PMR-AS, the clinical (clin)-PMR-AS and the imputed-CRP (imp-CRP)-PMR-AS have been developed to avoid such bias. Our
-
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS) RMD Open (IF 6.2) Pub Date : 2024-03-01 Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Objective To assess the risk of serious infection associated with different targeted therapies for psoriatic arthritis (PsA) in real-world settings. Methods This nationwide cohort study used the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database to identify all adults with PsA who were new users of targeted therapies (adalimumab, etanercept
-
Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial RMD Open (IF 6.2) Pub Date : 2024-03-01 Signe Møller-Bisgaard, Kim Hørslev-Petersen, Lykke Midtbøll Ørnbjerg, Bo Ejbjerg, Merete Lund Hetland, Jakob Møllenbach Møller, Sabrina Mai Nielsen, Daniel Glinatsi, Mikael Boesen, Kristian Stengaard-Pedersen, Ole Rintek Madsen, Bente Jensen, Jan Alexander Villadsen, Ellen Margrethe Hauge, Oliver Hendricks, Hanne Lindegaard, Niels Steen Krogh, Anne Grethe Jurik, Henrik Thomsen, Robin Christensen, Mikkel
Objective To investigate whether a 2-year MRI treat-to-target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-to-target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission. Methods IMAGINE-more was an observational
-
Internalisation of neutrophils extracellular traps by macrophages aggravate rheumatoid arthritis via Rab5a RMD Open (IF 6.2) Pub Date : 2024-03-01 Haixin Ye, Qian Yang, Huaxia Guo, Xing Wang, Lifang Cheng, Bingqi Han, Mukeng Hong, Fopei Ma, Meng Li, Xianghui Wu, Feilong Chen, Junqing Zhu, Shixian Chen, Songyuan Zheng, Juan Li
Objectives Although elevated levels of neutrophil extracellular traps (NETs) have been reported in patients with rheumatoid arthritis (RA), the role of NETs in RA and the relationship between NETs and macrophages in the pathogenesis of RA requires further research. Here, we sought to determine the role of NETs in RA pathogenesis and reveal the potential mechanism. Methods Neutrophil elastase (NE) and
-
Impact of filgotinib on pain control in the phase 3 FINCH studies RMD Open (IF 6.2) Pub Date : 2024-03-01 Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet Pope, Georg Pongratz, Bruno Fautrel, Rieke Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, Rene Westhovens
Objective This post hoc analysis of the FINCH 1–3 ([NCT02889796][1], [NCT02873936][2] and [NCT02886728][3]) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy in patients with rheumatoid arthritis (RA). Methods Assessments included: residual pain responses of ≤10 and ≤20 mm on a 100 mm visual analogue scale (VAS); the proportion of
-
The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD Consortium RMD Open (IF 6.2) Pub Date : 2024-03-01 Linyi Peng, Jingna Li, Jiaxin Zhou, Yunyun Fei, lingli Dong, Yan-Ying Liu, Dingding Zhang, Yanhong Wang, Shuhong Chi, Fang Wang, Yunxia Hou, Xiaoping Hong, Hongsheng Sun, Yujin Ye, Nan Che, Rong Zhang, Changyan Liu, Zongfei Ji, Wenjia Sun, Cheng Zhao, Ning Ma, Yamin Lai, Mengtao Li, Yan Zhao, Xiaofeng Zeng, Liwei Lu, Wen Zhang
Objective To develop and conduct an initial validation of the Damage Index for IgG4-related disease (IgG4-RD DI). Methods A draft of index items for assessing organ damages in patients with IgG4-RD was generated by experts from the Chinese IgG4-RD Consortium (CIC). The preliminary DI was refined using the Delphi method, and a final version was generated by consensus. 40 IgG4-RD cases representing four
-
Disease activity trajectories from childhood to adulthood in the population-based Nordic juvenile idiopathic arthritis cohort RMD Open (IF 6.2) Pub Date : 2024-03-01 Veronika Rypdal, Mia Glerup, Martin Rypdal, Ellen Arnstad, Kristiina Aalto, Lillemor Berntson, Anders Fasth, Troels Herlin, Charlotte Myrup, Suvi Peltoniemi, Marite Rygg, Ellen Berit Nordal
Objectives To identify long-term disease activity trajectories from childhood to adulthood by using the clinical Juvenile Arthritis Disease Activity Score (cJADAS10) in juvenile idiopathic arthritis (JIA). Second, to evaluate the contribution of the cJADAS10 components and explore characteristics associated with active disease at the 18-year follow-up. Methods Patients with onset of JIA in 1997–2000
-
Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation RMD Open (IF 6.2) Pub Date : 2024-03-01 Abhishek Abhishek, Matthew Grainge, Tim Card, Hywel C Williams, Maarten W Taal, Guruprasad P Aithal, Christopher P Fox, Christian D Mallen, Matthew D Stevenson, Georgina Nakafero, Richard Riley
Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping monitoring after 1 year. To rationalise monitoring, we developed and validated a prognostic model for clinically significant blood, liver or kidney toxicity
-
Hyperactivation and altered selection of B cells in patients with paediatric Sjogren’s syndrome RMD Open (IF 6.2) Pub Date : 2024-03-01 Alessandra Boni, Rebecca Nicolai, Ivan Caiello, Francesca Marinaro, Luciapia Farina, Denise Pires Marafon, Rita Carsetti, Fabrizio De Benedetti, Claudia Bracaglia, Emiliano Marasco
Objectives Paediatric Sjögren’s syndrome (pSS) is a rare chronic autoimmune disorder, characterised by inflammation of exocrine glands. B cell hyperactivation plays a central role in adult-onset Sjogren. This study was designed to analyse B cell and T cell phenotype, levels of BAFF, and selection of autoreactive B cells in patients with pSS. Methods A total of 17 patients diagnosed with pSS and 13
-
Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System RMD Open (IF 6.2) Pub Date : 2024-03-01 Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik
Objectives Biosimilar-originator equivalence has been demonstrated in phase 3 trials in a few indications of infliximab, etanercept and adalimumab. The objective of our study was to compare the persistence and safety of biosimilars versus originators in all the licensed indications of these molecules. Methods We used data from the French National Health Data System (SNDS), covering 99% of the French
-
Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study RMD Open (IF 6.2) Pub Date : 2024-02-01 Anna Zubrzycka-Sienkiewicz, Kamilla Klama, Martin Ullmann, Corinne Petit-Frere, Peter Baker, Joëlle Monnet, Andras Illes
Objective To evaluate the efficacy, immunogenicity and safety of the proposed biosimilar MSB11456 versus European Union (EU)-approved tocilizumab reference product in patients with rheumatoid arthritis (RA) in a multicentre, randomised, double-blind, multinational, parallel-group study ([NCT04512001][1]). Methods Adult patients with moderate-to-severe active RA and inadequate clinical response to ≥1
-
Epidemiology and clinical characteristics of biopsy-confirmed adult-onset IgA vasculitis in southern Sweden RMD Open (IF 6.2) Pub Date : 2024-02-01 Michaela Thalen, Karl Gisslander, Mårten Segelmark, Jacob Sode, David Jayne, Aladdin J Mohammad
Objective Immunoglobulin A vasculitis (IgAV) is the most prevalent primary childhood vasculitis in Sweden, but is considerably rarer in adults. This study aims to describe the epidemiology, clinical characteristics and renal outcome of adult-onset IgAV in Skåne, Sweden. Methods The study area consisted of Skåne, the southernmost region of Sweden, with a population ≥18 years of 990 464 on 31 December
-
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index RMD Open (IF 6.2) Pub Date : 2024-02-01 Silvia Rosina, Alessandro Consolaro, Angela Pistorio, Ana Rebollo-Giménez, Claudia Bracaglia, Pavla Dolezalova, Ana Guilaisne Bernard-Medina, Troels Herlin, Maria Trachana, Veronika Vargová, Carine Wouters, Laura Carenini, Nicolino Ruperto, Angelo Ravelli
Objectives To develop and validate the cut-offs in the Juvenile DermatoMyositis Activity Index (JDMAI) to distinguish the states of inactive disease (ID), low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA) in children with juvenile dermatomyositis (JDM). Methods For cut-off definition, data from 139 patients included in a randomised clinical trial were used
-
Health inequities and societal costs for patients with fibromyalgia and their spouses: a Danish cohort study RMD Open (IF 6.2) Pub Date : 2024-02-01 Kirstine Amris, Rikke Ibsen, Pernille Hurup Duhn, Judi Olsen, Karoline Lolk, Jakob Kjellberg, Lars Erik Kristensen
Objective To assess the burden of illness of people with fibromyalgia (FM) and their spouses compared with selected match populations in Denmark. Methods Population-based, cohort case-control study using data from Danish registries from 1994 to 2021. Individuals with an FM diagnosis were identified from the National Patient Register (2008–2019) and randomly matched to a 1:4 general population comparator
-
Estimated prevalence, incidence and healthcare costs of Sjögren’s syndrome in France: a national claims-based study RMD Open (IF 6.2) Pub Date : 2024-02-01 Raphaele Seror, Laurent Chiche, Maxime Beydon, Guillaume Desjeux, Joe Zhuo, Virginie Vannier-Moreau, Valérie Devauchelle-Pensec
Objectives To estimate prevalence, incidence and mortality rates, and annual healthcare costs of primary Sjögren’s syndrome (pSS) and SS associated with other autoimmune disorders (SS+AID) in France. Methods French national healthcare claims-based study within the prospective Système National des Données de Santé database that includes the majority of the French population. An algorithm was developed
-
Altered dynamic functional network connectivity in rheumatoid arthritis associated with peripheral inflammation and neuropsychiatric disorders RMD Open (IF 6.2) Pub Date : 2024-02-01 Yanmin Zheng, Zhiduo Hou, Shuhua Ma, Zikai Huang, Jianhua Peng, Shuxin Huang, Ruiwei Guo, Jinzhuang Huang, Zhirong Lin, Zelin Zhuang, Jingjing Yin, Lei Xie
Objective This study explored the dynamic functional connective (DFC) alterations in patients with rheumatoid arthritis (RA) and investigated the correlation between the neuropsychiatric symptoms, peripheral inflammation and DFC alterations. Method Using resting-state functional MRI, we investigated the DFC based on spatial independent component analysis and sliding window method for 30 patients with
-
Characterisation of airway disease associated with Sjögren disease RMD Open (IF 6.2) Pub Date : 2024-02-01 Loïc Meudec, Marie-Pierre Debray, Antoine Beurnier, Cindy Marques, Pierre-Antoine Juge, Robin Dhote, Claire Larroche, Anne Laure Fauchais, Emanuelle Dernis, Olivier Vittecoq, Alain Saraux, Jacques-Eric Gottenberg, Eric Hachulla, Véronique Le Guern, Philippe Dieudé, Raphaele Seror, Xavier Mariette, Gaétane Nocturne
Objective Although airway disease associated with Sjögren’s disease (Sjo-AD) is common, it is poorly studied compared with interstitial lung disease (ILD). In this study, we aimed to assess factors associated with Sjo-AD, the characteristics and prognosis of this manifestation. Methods We performed a retrospective multicentric study involving nine centres. We included Sjo-AD patients confirmed by at
-
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study RMD Open (IF 6.2) Pub Date : 2024-02-01 Maxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, Pascal Claudepierre, Philippe Goupille, Adeline Ryussen-Witrand, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas
Objective To compare the 1-year retention rate of secukinumab in axial spondyloarthritis (axSpA) and its predisposing factors with regard to its time of initiation (eg, right after or remotely from its launch). Methods Study design: Retrospective multicentre French study of patients with axSpA. Study periods: Two cohorts were evaluated regarding the time of initiation of secukinumab: cohort 1 (C1)—between
-
Factors associated with satisfaction with social roles and activities among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort cross-sectional study RMD Open (IF 6.2) Pub Date : 2024-02-01 Tiffany Dal Santo, Danielle Rice, Marie-Eve Carrier, Gabrielle Virgili-Gervais, Brooke Levis, Linda Kwakkenbos, Susan J Bartlett, Amy Gietzen, Karen Gottesman, Genevieve Guillot, Marie Hudson, Laura K Hummers, Vanessa Malcarne, Maureen Mayes, Luc Mouthon, Michelle Richard, Maureen Sauve, Robyn Wojeck, Marie-Claude Geoffroy, Andrea Benedetti, Brett Thombs
Objective The objectives were to (1) compare satisfaction with social roles and activities in a large multinational systemic sclerosis (SSc) cohort to general population normative data and (2) identify sociodemographic, lifestyle and SSc disease factors associated with satisfaction with social roles and activities. Methods Participants in the Scleroderma Patient-centered Intervention Network Cohort
-
Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis RMD Open (IF 6.2) Pub Date : 2024-02-01 Paul J Scherbacher, Bernhard Hellmich, You-Shan Feng, Christian Löffler
Objective Glucocorticoids (GC) are a cornerstone in treating antineutrophil cytoplasmic antibodies-associated vasculitides (AAV), however, they add to morbidity and mortality. To date, GC toxicity in AAV has rarely been systematically investigated. Methods Patients with a confirmed AAV were included in this monocentric prospective study. GC toxicity was assessed by structured interviews, clinical examination
-
Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open (IF 6.2) Pub Date : 2024-02-01 Selinde V J Snoeck Henkemans, Pascal H P de Jong, Jolanda J Luime, Marc R Kok, Ilja Tchetverikov, Lindy-Anne Korswagen, Sjoerd M van der Kooij, Maikel van Oosterhout, Paul Baudoin, Jessica Bijsterbosch, Jos H van der Kaap, Annette H M van der Helm-van Mil, Marijn Vis
Objectives To investigate whether there is a window of opportunity for psoriatic arthritis (PsA) patients and to assess which patient characteristics are associated with a longer diagnostic delay. Methods All newly diagnosed, disease-modifying antirheumatic drug-naïve PsA patients who participated in the Dutch southwest Early PsA cohoRt and had ≥3 years of follow-up were studied. First, total delay
-
Long-term effectiveness of a lifestyle intervention for rheumatoid arthritis and osteoarthritis: 1-year follow-up of the ‘Plants for Joints’ randomised clinical trial RMD Open (IF 6.2) Pub Date : 2024-02-01 Carlijn A Wagenaar, Wendy Walrabenstein, Marike van der Leeden, Franktien Turkstra, Martijn Gerritsen, Jos W R Twisk, Maarten Boers, Martin van der Esch, Henriët van Middendorp, Peter J M Weijs, Dirkjan van Schaardenburg
Objectives In two randomised controlled trials, the Plants for Joints (PFJ) multidisciplinary lifestyle intervention reduced signs and symptoms of rheumatoid arthritis (RA), or metabolic syndrome-associated hip or knee osteoarthritis (MSOA) compared with usual care. The current study investigated long-term outcomes. Methods After completion of two 16-week trials in people with (1) RA or (2) MSOA, control
-
Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis RMD Open (IF 6.2) Pub Date : 2024-02-01 Wenhui Xie, Yue Hou, Shiyu Xiao, Xiaolin Zhang, Zhuoli Zhang
Background Dysregulation of several inflammatory cytokines including tumour necrosis factor (TNF) in dementia patients has also been identified as a key factor in the pathogenesis of rheumatoid arthritis (RA). We aimed to investigate the association of disease-modifying antirheumatic drugs (DMARDs) therapy for RA with risk of incident dementia. Methods Electronic database searches of PubMed, EMBASE
-
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL RMD Open (IF 6.2) Pub Date : 2024-02-01 Laura C Coates, Robert Landewé, Iain B McInnes, Philip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana-Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors. Methods Patients completing the 16-week phase III double-blind, placebo-controlled BE COMPLETE ([NCT03896581][1]) study entered the open-label extension, BE VITAL ([NCT04009499][2]). All patients in BE VITAL
-
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study RMD Open (IF 6.2) Pub Date : 2024-02-01 Clementina López-Medina, Jerusalem Calvo-Gutiérrez, M Carmen Ábalos-Aguilera, Francisco Cepas, Chamaida Plasencia-Rodríguez, Ana Martínez-Feito, Alejandro Balsa, Regina Faré-García, Antoni Juan-Mas, Virginia Ruiz-Esquide, Luis Sainz, César Díaz-Torné, Francisco Javier Godoy-Navarrete, Isabel Añón-Oñate, Natalia Mena-Vázquez, Sara Manrique-Arija, Marina Soledad Moreno-García, Rafaela Ortega-Castro,
Objective To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Methods Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions
-
Exploring radiographic patterns of the cervical spine, including zygapophyseal joints, in axial spondyloarthritis RMD Open (IF 6.2) Pub Date : 2024-02-01 Laura Berbel-Arcobé, Diego Benavent, Xabier Michelena, José Antonio Narváez, Joan Miquel Nolla, Xavier Juanola
Introduction The assessment of the cervical spine (CS) in axial spondyloarthritis (axSpA) and its radiographic characteristics, including the zygapophyseal joints (ZJ), may be helpful for an accurate diagnosis, establishing a prognosis and enhancing treatment decisions. Objectives To describe the prevalence and characteristics of CS involvement in patients with axSpA and perform a comparison between
-
Patients with ankylosing spondylitis present a distinct CD8 T cell subset with osteogenic and cytotoxic potential RMD Open (IF 6.2) Pub Date : 2024-02-01 Veronica Martini, Ylenia Silvestri, Adrian Ciurea, Burkhard Möller, Gabriela Danelon, Flavio Flamigni, David Jarrossay, Ivo Kwee, Mathilde Foglierini, Andrea Rinaldi, Valentina Cecchinato, Mariagrazia Uguccioni
Objectives Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease affecting mainly the axial skeleton. Peripheral involvement (arthritis, enthesitis and dactylitis) and extra-musculoskeletal manifestations, including uveitis, psoriasis and bowel inflammation, occur in a relevant proportion of patients. AS is responsible for chronic and severe back pain caused by local inflammation
-
New blood biomarkers and imaging for disease stratification and monitoring of giant cell arteritis RMD Open (IF 6.2) Pub Date : 2024-02-01 Alessandro Tomelleri, Christian Dejaco
Relapses and late complications remain a concern in giant cell arteritis (GCA). Monitoring strategies are required to effectively tailor treatment and improve patients’ outcomes. Current monitoring of GCA is based on clinical assessment and evaluation of traditional inflammatory markers such as C reactive protein and erythrocyte sedimentation rate; however, this approach has limited value in patients
-
Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs RMD Open (IF 6.2) Pub Date : 2024-02-01 Shotaro Kojima, Taro Iwamoto, Yoshihisa Kobayashi, Manami Kato, Fumiyoshi Takizawa, Tomoaki Ida, Junya Suzuki, Yosuke Toda, Kazusa Miyachi, Arifumi Iwata, Shunsuke Furuta, Kei Ikeda, Hiroshi Nakajima
Objectives This study aimed to determine the immunogenicity and the influence on disease activity of an adjuvanted recombinant varicella-zoster virus (VZV) subunit vaccine (RZV) in patients with rheumatoid arthritis (RA) treated with disease-modifying antirheumatic drugs (DMARDs). Methods This prospective longitudinal study enrolled 53 patients with RA (aged ≥50 years) treated with DMARDs (conventional
-
Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway RMD Open (IF 6.2) Pub Date : 2024-02-01 Ingebjørg Tronstad, Mari Hoff, Julie Horn, Sigrid Anna Aalberg Vikjord, Vibeke Videm, Jonas Johansson, Tom Ivar Lund Nilsen, Arnulf Langhammer
Objectives Rheumatoid arthritis has been associated with increased fracture risk. New treatments have improved the course of the disease substantially, but it is not clear if this influences fracture risk. We examined if rheumatoid arthritis, overall and according to disease-modifying antirheumatic drugs (DMARDs), is associated with a risk of major osteoporotic fractures. Methods Overall, 92 285 participants
-
Patient-reported outcomes and radiographic progression in patients with rheumatoid arthritis in sustained remission versus low disease activity RMD Open (IF 6.2) Pub Date : 2024-02-01 Selinde V J Snoeck Henkemans, Marijn Vis, Agnes E M Looijen, Annette H M van der Helm-van Mil, Pascal H P de Jong
Objective To compare clinical and patient-reported outcomes (PROs) over 5 years between patients with rheumatoid arthritis (RA) in sustained remission (sREM), sustained low disease activity (sLDA) or active disease (AD) in the first year after diagnosis. Methods All patients with RA from the treatment in the Rotterdam Early Arthritis CoHort trial, a multicentre, stratified, single-blinded trial with
-
Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritis RMD Open (IF 6.2) Pub Date : 2024-02-01 Philip M Brown, Amy E Anderson, Najib Naamane, Dennis W Lendrem, Ann W Morgan, John D Isaacs, Arthur G Pratt
Objectives Long-term outcomes in rheumatoid arthritis (RA) depend on early and effective disease control. Methotrexate (MTX) remains the first-line disease modifying therapy, however there are no biomarkers with which to identify those most likely to achieve remission. To address this unmet need we explored metabolic pathways involved in MTX mechanism of action within circulating CD4+T cells in a cohort
-
Correction: Hepatitis B vaccination associated with low response in patients with rheumatic diseases treated with biologics RMD Open (IF 6.2) Pub Date : 2024-02-01 EULAR
Romão VC, Ávila-Ribeiro P, Gonçalves MJ, et al . Hepatitis B vaccination associated with low response in patients with rheumatic diseases …
-
Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry RMD Open (IF 6.2) Pub Date : 2024-02-01 Jasmin B Kuemmerle-Deschner, Tilmann Kallinich, Joerg Henes, Birgit Kortus-Götze, Prasad T Oommen, Juergen Rech, Tobias Krickau, Frank Weller-Heinemann, Gerd Horneff, Aleš Janda, Ivan Foeldvari, Catharina Schuetz, Frank Dressler, Michael Borte, Markus Hufnagel, Florian Meier, Michael Fiene, Ioana Andreica, Julia Weber-Arden, Norbert Blank
Objective Interim analysis of the RELIANCE registry, an on-going, non-interventional, open-label, multicentre, prospective study evaluating the long-term safety, dosing regimens and effectiveness of canakinumab in patients with cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), tumour-necrosis factor receptor-associated periodic syndrome (TRAPS) or mevalonate-kinase
-
Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs RMD Open (IF 6.2) Pub Date : 2024-02-01 Fares Al Mohamad, Valeria Rios Rodriguez, Hildrun Haibel, Mikhail Protopopov, Judith Rademacher, Joachim Sieper, Murat Torgutalp, Henriette Käding, Fabian Proft, Denis Poddubnyy
Objective To evaluate the association of nociplastic (NoP) and neuropathic pain (NP) components with residual symptoms in patients with radiographic axial spondyloarthritis (r-axSpA) receiving biological disease-modifying antirheumatic drugs (bDMARDs). Methods 78 patients with r-axSpA from the GErman SPondyloarthritis Inception Cohort receiving a bDMARD for at least 3 months were included in this analysis
-
Entry point of machine learning in axial spondyloarthritis RMD Open (IF 6.2) Pub Date : 2024-02-01 Yuening Chen, Hongxiao Liu, Qing Yu, Xinning Qu, Tiantian Sun
Axial spondyloarthritis (axSpA) is a globally prevalent and challenging autoimmune disease. Characterised by insidious onset and slow progression, the absence of specific clinical manifestations and biomarkers often leads to misdiagnosis, thereby complicating early detection and diagnosis of axSpA. Furthermore, the high heterogeneity of axSpA, its complex pathogenesis and the lack of specific drugs
-
Intensive training programme for ultrasound-guided minimally invasive synovial tissue biopsy on knees and wrists in different phases of inflammation RMD Open (IF 6.2) Pub Date : 2024-02-01 Lavinia Agra Coletto, Valentina Marino, Chiara Rizzo, Natacha Goulas, Pietro Rubortone, Lucrezia Verardi, Emanuela Gaggiano, Dario Bruno, Arianna D’Antonio, Marco Gessi, Clara Di Mario, Barbara Tolusso, Laura Bui, Roberta Benvenuto, Maria Sole Chimenti, Giuliana Guggino, Francesco Ciccia, Roberto Caporali, Elisa Gremese, Marco Maria Lizzio, Maria-Antonietta D’Agostino, Stefano Alivernini
Objectives To develop an intensive training programme for ultrasound (US)-guided synovial tissue (ST) biopsy on knees and wrists in inflammatory arthritis and to assess the learning curve, patient tolerability, sample quality and trainees’ expectations. Methods Active or remission rheumatoid arthritis patients were enrolled. Nine trainees joined the 4-month programme in a centre experienced in performing
-
Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarth RMD Open (IF 6.2) Pub Date : 2024-02-01 Walter Maksymowych, Anna Enevold Fløistrup E F Hadsbjerg, Mikkel Østergaard, Raphael Micheroli, Susanne Juhl Pedersen, Adrian Ciurea, Nora Vladimirova, Michael S Nissen, Kristyna Bubova, Stephanie Wichuk, Manouk de Hooge, Ashish J Mathew, Karlo Pintaric, Monika Gregová, Ziga Snoj, Marie Wetterslev, Karel Gorican, Burkhard Möller, Iris Eshed, Joel Paschke, Robert GW Lambert
Background The Spondyloarthritis Research Consortium of Canada (SPARCC) developers have created web-based calibration modules for the SPARCC MRI sacroiliac joint (SIJ) scoring methods. We aimed to test the impact of applying these e-modules on the feasibility and reliability of these methods. Methods The SPARCC-SIJ RETIC e-modules contain cases with baseline and follow-up scans and an online scoring
-
Correction: Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial RMD Open (IF 6.2) Pub Date : 2024-02-01 EULAR
Kragsnaes MS, Jensen JRB, Nilsson AC, et al . Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis …
-
Metabolic and molecular imaging in inflammatory arthritis RMD Open (IF 6.2) Pub Date : 2024-02-01 Rita Noversa de Sousa, Koray Tascilar, Giulia Corte, Armin Atzinger, Ioanna Minopoulou, Sarah Ohrndorf, Maximilian Waldner, Christian Schmidkonz, Torsten Kuwert, Ferdinand Knieling, Arnd Kleyer, Andreas Ramming, Georg Schett, David Simon, Filippo Fagni
It is known that metabolic shifts and tissue remodelling precede the development of visible inflammation and structural organ damage in inflammatory rheumatic diseases such as the inflammatory arthritides. As such, visualising and measuring metabolic tissue activity could be useful to identify biomarkers of disease activity already in a very early phase. Recent advances in imaging have led to the development
-
Eosinopenia and routine inflammatory biomarkers are helpful for the diagnosis of infection in patients treated with IL-6 pathway antagonists RMD Open (IF 6.2) Pub Date : 2024-02-01 Audrey Glatre, Madeline Pascard, Maxime Hentzien, Jean Hugues Salmon, Amélie Servettaz, Ailsa Robbins
Patients with inflammatory diseases such as rheumatoid arthritis treated with IL-6 pathway antagonists are particularly prone to potentially serious infections. However, diagnosis of such events can be hindered by the normality of usual inflammatory biomarkers such as C reactive protein (CRP). In this retrospective monocentric study, we included all patients treated with tocilizumab for an inflammatory
-
Non-invasive biomarkers of disease activity and organ damage in ANCA-associated vasculitis: a systematic review RMD Open (IF 6.2) Pub Date : 2024-02-01 Thomas Renson, Margaret M Kelly, Hallgrimur Benediktsson, Nele Grundhoefer, Nadia Luca, Paivi Miettunen, Marinka Twilt, Silviu Grisaru, Andrew Wade, Anke Banks, Aurore Fifi-Mah, Lorraine Hamiwka, Susanne Benseler
Background In anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), histopathological assessment of affected tissue is often necessary for diagnosis and assessment of disease extent. There is a requirement for validated non-invasive biomarkers to avoid the need for serial tissue biopsies. Methods A systematic review of scientific databases from 2012 until present was performed to
-
PM10 increases mortality risk in rheumatoid arthritis-associated interstitial lung disease RMD Open (IF 6.2) Pub Date : 2024-02-01 Soo Han Kim, Sun-Young Kim, Hee-Young Yoon, Jin Woo Song
Objectives The effect of air pollution on the prognosis of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) remains poorly understood. We aimed to evaluate the effect of long-term exposure to particulate matter with an aerodynamic diameter of ≤10 µm (PM10) and nitrogen dioxide (NO2) on mortality in patients with RA-ILD. Methods We included 309 patients (mean age, 61.7 years; male
-
Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years RMD Open (IF 6.2) Pub Date : 2024-02-01 Mohanad M Elfishawi, Mahmut S Kaymakci, Sara J Achenbach, Cynthia S Crowson, Tanaz A Kermani, Cornelia M Weyand, Matthew J Koster, Kenneth J Warrington
Objective To evaluate the incidence and outcomes of large artery (LA) involvement among patients with giant cell arteritis (GCA) and to compare LA involvement to non-GCA patients. Methods The study included Olmsted County, Minnesota, USA residents with incident GCA between 1950 and 2016 with follow-up through 31 December 2020, death or migration. A population-based age-matched/sex-matched comparator
-
Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation RMD Open (IF 6.2) Pub Date : 2024-01-01 Hui Jiang, Yu Shi, Wei Liu, Bao Liu, Yue-Xin Chen, Yangzhong Zhou, Can Huang, Qian Wang, Xinping Tian, Yan Zhao, Mengtao Li, Xiaofeng Zeng, Jiuliang Zhao
Objective Chronic abdominal aortic occlusive disease (CAAOD) is an uncommon manifestation of antiphospholipid syndrome (APS), impacting cardiovascular health and peripheral arterial circulation. We investigated CAAOD in antiphospholipid antibodies (aPL)-positive patients, aimed to offer comprehensive clinical and radiological insights. Methods aPL-positive patients with arterial thrombotic events were
-
Neoehrlichia mikurensis is uncommon in rheumatological patients receiving tumour necrosis factor inhibitors and in blood donors: a retrospective cohort study RMD Open (IF 6.2) Pub Date : 2024-01-01 Rosa Gynthersen, Mathilde Ørbæk, Estrid Høgdall, Bente Glintborg, Sisse Rye Ostrowski, Lene Harritshøj, Merete Lund Hetland, Anne-Mette Lebech, Helene Mens
Introduction Neoehrlichia mikurensis is a tick-borne bacterium that primarily causes disease in immunocompromised patients. The bacterium has been detected in ticks throughout Europe, with a 0%–25% prevalence. N. mikurensis infection presents unspecific symptoms, which can easily be mistaken for inflammatory disease activity. We aimed to determine the prevalence of N. mikurensis in rheumatological
-
History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis RMD Open (IF 6.2) Pub Date : 2024-01-01 Claire De Moreuil, Elizabeth Diot, Christian Agard, Nicolas Belhomme, Alain Lescoat, Viviane Queyrel, Nathalie Tieulie, Marie-Elise Truchetet, Grégory Pugnet, Sabine Berthier, Perrine Smets, Benjamin Subran, Olivier Lidove, Jeremy Keraen, Arsène Mekinian, Emmanuel Chatelus, Elisabeth Pasquier, Emilie Brenaut, Bénedicte Rouvière, Mathieu Delplanque, Sandy Lucier, Emmanuelle Courtois-Communier, Valérie
Background Vascular phenotype is associated with a poor prognosis in systemic sclerosis (SSc). The identification of its risk factors could facilitate its early detection. Objectives To explore risk factors for a vascular phenotype of SSc, among them a history of pre-eclampsia. Methods This observational multicentre case–control study enrolled adult women fulfilling European Alliance of Associations
-
Severe methotrexate toxicity in elderly patients under diuretics RMD Open (IF 6.2) Pub Date : 2024-01-01 Cara Kumar, Matthias Kuhn, Kristine Herrmann, Nicolai Leuchten, Martin Aringer
Objectives To explore the toxicity of low-dose methotrexate (MTX), an uncommon, but life-threatening event. Methods We analysed the presentation, course and risk factors of all patients admitted to the rheumatology ward with severe low-dose MTX toxicity. These patients were compared with patients without signs of relevant MTX toxicity. Results The 12 patients admitted for MTX toxicity included 7 patients
-
Association between sinusitis and incident rheumatic diseases: a population-based study RMD Open (IF 6.2) Pub Date : 2024-01-01 Vanessa L Kronzer, John M Davis, Andrew C Hanson, Jeffrey A Sparks, Elena Myasoedova, Ali Duarte-Garcia, Alicia M Hinze, Ashima Makol, Mattew J Koster, Robert Vassallo, Kenneth J Warrington, Kerry Wright, Cynthia S Crowson
Objectives To determine whether antecedent sinusitis is associated with incident rheumatic disease. Methods This population-based case–control study included all individuals meeting classification criteria for rheumatic diseases between 1995 and 2014. We matched three controls to each case on age, sex and length of prior electronic health record history. The primary exposure was presence of sinusitis
-
Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease RMD Open (IF 6.2) Pub Date : 2024-01-01 Johanna Bausson, Nicolas Keller, Jean-Jacques Von Hunolstein, Matthieu Sacrez, Bruno Michel, Bénédicte Gourieux, Marion Fourtage, Renaud Felten
Introduction Colchicine, commonly used in gout flare, is contraindicated in severe chronic kidney disease (CKD) (estimated glomerular filtration rate <30 mL/min). However, in this context, there are few alternatives, and colchicine use persists. We evaluated the tolerance of colchicine and its efficacy in patients with severe CKD. Patients and methods All prescriptions of colchicine for managing crystal-induced
-
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis RMD Open (IF 6.2) Pub Date : 2024-01-01 Laure Gossec, Ana-Maria Orbai, Laura C Coates, Dafna D Gladman, Alexis Ogdie, Christopher G Pelligra, Valérie Ciaravino, Barbara Ink, Vanessa Taieb, Jérémy Lambert, Maarten de Wit
Objectives To investigate psychometric performance of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) total and individual item scores in patients with psoriatic arthritis (PsA) and to estimate score change thresholds and scores corresponding to different levels of symptom/impact severity. Methods Data up to week 16 from 1252 patients with active PsA enrolled in two randomised controlled
-
Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis RMD Open (IF 6.2) Pub Date : 2024-01-01 Philip J Mease, Soumya Reddy, Sarah Ross, Jeffrey R Lisse, Paulo Reis, Kirstin Griffing, Christophe Sapin, Aisha Vadhariya, Daniel E Furst
Introduction An important consideration in the treatment of patients with psoriatic arthritis (PsA) is whether the addition of methotrexate (MTX) to biologics has greater efficacy than biologic monotherapy with respect to efficacy outcomes in these patients. Objectives To conduct a network meta-analysis (NMA) comparing biologics by treatment class with and without MTX for treatment of adults with active
-
Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases RMD Open (IF 6.2) Pub Date : 2024-01-01 Mauro Fatica, Benedetta Monosi, Paola Conigliaro, Arianna D’Antonio, Sara Essofi, Elisa Cuccagna, Alberto Bergamini, Livia Biancone, Giovanni Monteleone, Paola Triggianese, Emma Calabrese, Maria Sole Chimenti
Objective Evaluate spondyloarthritis (SpA) incidence in inflammatory bowel diseases (IBD) between patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) and conventional DMARDs (cDMARDs) and define risk factors associated with SpA development. Methods Retrospective cohort study was conducted on patients with Crohn’s disease (CD) or ulcerative colitis (UC) and divided into
-
Comparison of the ASAS Health Index in patients classified as radiographic axial spondyloarthritis (axSpA) or non-radiographic axSpA in the ASAS Health Index international validation study RMD Open (IF 6.2) Pub Date : 2024-01-01 Warren Fong, Ting Hui Woon, Yu Heng Kwan, Jürgen Braun, Désirée van der Heijde, Annelies Boonen, Uta Kiltz
Objectives To determine if there were differences in the Assessment of SpondyloArthritis international Society Health Index (ASAS HI) scores between patients classified as radiographic axial spondyloarthritis (r-axSpA) and non-radiographic axSpA (nr-axSpA), and to identify factors associated with higher ASAS HI scores in both disease phenotypes. Methods This study was an ancillary analysis of the ASAS
-
Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning RMD Open (IF 6.2) Pub Date : 2024-01-01 Jose A Román Ivorra, Ernesto Trallero-Araguas, Maria Lopez Lasanta, Laura Cebrián, Leticia Lojo, Belén López-Muñíz, Julia Fernández-Melon, Belén Núñez, Lucia Silva-Fernández, Raúl Veiga Cabello, Pilar Ahijado, Isabel De la Morena Barrio, Nerea Costas Torrijo, Belén Safont, Enrique Ornilla, Juliana Restrepo, Arantxa Campo, Jose L Andreu, Elvira Díez, Alejandra López Robles, Elena Bollo, Diego Benavent
Objectives Real-world data regarding rheumatoid arthritis (RA) and its association with interstitial lung disease (ILD) is still scarce. This study aimed to estimate the prevalence of RA and ILD in patients with RA (RAILD) in Spain, and to compare clinical characteristics of patients with RA with and without ILD using natural language processing (NLP) on electronic health records (EHR). Methods Observational